Don't tell nuclear medicine vendorTrionix that you can't fight the Radiological Society of NorthAmerica. The Twinsburg, OH, company is returning to the RSNA'stechnical exhibit after sitting out last year because of a disputewith the meeting's organizers
Don't tell nuclear medicine vendorTrionix that you can't fight the Radiological Society of NorthAmerica. The Twinsburg, OH, company is returning to the RSNA'stechnical exhibit after sitting out last year because of a disputewith the meeting's organizers over its booth location.
Trionix suffered through the 1992 and 1991 meetings with abooth located in the nether regions of the exhibit hall, nearthe entrance area for mobile trucks in the back of the hall. RSNAorganizers tried to assign the vendor the same spot for last year'smeeting, but the company balked. When the RSNA refused to giveTrionix a new location the company pulled out of the meeting,according to president Chun Bin Lim (SCAN 10/6/93).
This year, the society was more accommodating and gave Trionixa space closer to the central area of the technical exhibit floor.The company's return to the exhibit was also influenced by a strategicdecision to place more emphasis on U.S. sales and marketing. Trionixspent much of last year targeting international sales of its gammacameras.
At next week's meeting, Trionix will showcase its Triad XLT20, a triple-head gamma camera with larger detectors than theTriad XLT. Each detector on the Triad XLT 20 has a 20 x 15-inchfield-of-view, making it optimal for whole-body studies. Trionixunveiled the camera at this year's Society of Nuclear Medicinemeeting in Orlando (SCAN 6/29/94). At the RSNA conference, Trionixwill display for the first time the results of clinical studiesusing the camera, which has Food and Drug Administration 510(k)clearance.
Trionix will also feature its latest work in 511-KeV imagingusing high-energy collimators, as well as the Biad XLT and TriadXLT gamma cameras.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.